Tradestie Institutional Equity Comparison Engine

ORIC vs MLTX โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

MLTX Overall Edge

MLTX Captures Institutional Edge (2โ€“1 Pillars ยท 3โ€“2 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to MoonLake Immunotherapeutics Class A Ordinary Shares (MLTX) driven by superior Momentum & Technical, Options & Structure while ORIC counters with relative strength in Growth & Margin. Fundamentally, ORIC trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus MLTX at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, ORIC sits in BREAKDOWN (77th %ile IV; Dealer Gamma Walls on Pro) against MLTX sits in BREAKDOWN (7th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
ORIC N/M vs MLTX N/M Fwd P/E
Growth & Margin Winner ORIC
Op Margin 0.0% vs 0.0% ยท YoY +0.0% vs +0.0%
Momentum & Technical Winner MLTX
1Y -37.0% vs -5.7% ยท 52W Pos 6% vs 17%
Options & Structure Winner MLTX
BREAKDOWN (77th %ile IV) vs BREAKDOWN (7th %ile IV)
ORIC NASDAQ
Oric Pharmaceuticals, Inc. Common Stock
Pharmaceutical Preparations
$7.68
-2.23% 1D
Market Cap $881.0M
1M Return -37.77%
1Y Return -36.96%
Forward P/E N/M
Unified AI Score
46.2 / 100 HOLD
Tech 33.0 Fund 51.0 Flow 63.0 Mom 60.0
MLTX NASDAQ
MoonLake Immunotherapeutics Class A Ordinary Shares
Pharmaceutical Preparations
$11.85
-5.2% 1D
Market Cap $1.1B
1M Return +24.08%
1Y Return -5.65%
Forward P/E N/M
Unified AI Score
38.3 / 100 SELL
Tech 32.0 Fund 44.0 Flow 75.0 Mom 50.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: ORIC -36.96% MLTX -5.65% Spread: +31.31 pp (MLTX Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
ORIC TTM Op. Margin: 0.0% MLTX TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ORIC vs MLTX. Trailing 12-month operating profitability (ORIC 0.0% vs MLTX 0.0%) and valuation multiples (ORIC N/M vs MLTX N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: ORIC (2) vs MLTX (3)
Institutional Metric ORIC MLTX Criterion Row Winner
Market Capitalization Scale $881.0M $1.1B Larger Scale MLTX
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth +0.0% +0.0% Higher Growth Tie
Operating Margin (TTM) Profitability 0.0% 0.0% Higher Margin Tie
Net Profit Margin Profitability 0.0% 0.0% Higher Margin Tie
Return on Equity (ROE) Capital Efficiency -39.8% -81.5% Higher ROE ORIC
52-Week Range Position Momentum 6% ($7โ€“$15) 17% ($9โ€“$23) Stronger Trend MLTX
Beta / 30D Volatility Risk Regime 1.33ฮฒ ยท 129% Vol 1.61ฮฒ ยท 90% Vol Lower Realized Risk MLTX
Unified Institutional Score Composite Signal 46.2 / 100 (HOLD) 38.3 / 100 (SELL) Higher Composite ORIC

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full ORIC vs MLTX Buy Guide
ORIC BREAKDOWN
62d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 77th %ile
IV Regime Elevated (60thโ€“80th %ile)
Live ORIC Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
MLTX BREAKDOWN
103d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 7th %ile
IV Regime Compressed (<25th %ile)
Live MLTX Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither ORIC nor MLTX registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.